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Abstract In recent years study of rare human bone dis-
orders has led to the identiﬁcation of important signaling
pathways that regulate bone formation. Such diseases
include the bone sclerosing dysplasias sclerosteosis and
van Buchem disease, which are due to deﬁciency of scle-
rostin, a protein secreted by osteocytes that inhibits bone
formation by osteoblasts. The restricted expression pattern
of sclerostin in the skeleton and the exclusive bone phe-
notype of good quality of patients with sclerosteosis and
van Buchem disease provide the basis for the design of
therapeutics that stimulate bone formation. We review here
current knowledge of the regulation of the expression and
formation of sclerostin, its mechanism of action, and its
potential as a bone-building treatment for patients with
osteoporosis.
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Osteoporosis is characterized by low bone mass and mi-
croarchitectural deterioration of bone tissue with a conse-
quent increase in bone fragility and susceptibility to
fractures [1]. The balance between bone resorption and
bone formation determines the mass and structural integrity
of the skeleton and is disturbed in osteoporosis. Current
therapies of osteoporosis, with the exception of parathyroid
hormone (PTH), decrease the risk of osteoporotic fractures
by reducing bone resorption and preserving its architecture
but cannot stimulate bone formation. Elucidating the
mechanisms regulating bone formation may lead to the
development of therapeutics able to rebuild bone mass and
architecture.
In recent years, study of rare human bone disorders and
of genetically manipulated animal models has led to the
identiﬁcation of signaling pathways that regulate bone
formation, which provide potential targets for the devel-
opment of novel therapeutics. Fundamental for this pro-
gress have been studies of two rare bone sclerosing
dysplasias, sclerosteosis and van Buchem disease, that led
to the identiﬁcation of sclerostin, an important negative
regulator of bone formation.
Sclerosteosis and van Buchem Disease
Sclerosteosis (OMIM 269500) and van Buchem disease
(OMIM 239100) are two rare sclerosing bone disorders,
ﬁrst described in the 1950s as distinct clinical entities, with
closely related phenotypes [2]. Sclerosteosis has been
mainly diagnosed among Afrikaners of Dutch descent in
South Africa, while most patients diagnosed with van
Buchem disease come from a small ﬁshing village in The
Netherlands. A few individuals and families with scleros-
teosis or van Buchem disease have been reported in other
parts of the world, including Spain, Brazil, the United
States, Germany, Japan, Switzerland, and Senegal [3].
The skeletal manifestations of sclerosteosis and van
Buchem disease are the result of endosteal hyperostosis
and are characterized by progressive generalized osteo-
sclerosis [3–8]. The manifestations are most pronounced in
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DOI 10.1007/s00223-010-9372-1the mandible and skull, with characteristic enlargement of
the jaw and facial bones leading to facial distortion,
increased intracranial pressure, and entrapment of cranial
nerves, often associated with facial palsy, hearing loss, and/
or loss of smell (Fig. 1). Patients with sclerosteosis have a
more severe phenotype compared to patients with van
Buchem disease and usually have syndactyly. In a limited
number of bone biopsies of affected individuals, there is
evidence of increased bone formation including predomi-
nance of cuboidal active osteoblasts, increased double
tetracycline label spacing, and increased osteoid that min-
eralizes normally, while no consistent pattern of osteoclast
numbers or activity has been reported [9–12]. Information
about markers of bone turnover in such patients is also
limited. Beighton’s group reported elevated serum alkaline
phosphatase (AP) activity in the majority of patients with
sclerosteosis [13, 14], while Wergedal et al. [15] found
signiﬁcantly higher levels of bone formation (AP, procol-
lagen type 1 amino-terminal propeptide [P1NP], osteocal-
cin) and resorption (urinary amino-terminal type I collagen
telopeptide [NTX]) markers in six patients with van Bu-
chem disease compared to carriers of the disease.
The genetic defect that leads to sclerosteosis was iden-
tiﬁed in a newly cloned gene called SOST, which is located
on chromosome 17q12-21 and encodes for the protein
sclerostin. Five mutations have so far been identiﬁed in
patients with sclerosteosis, of which three introduce a
premature termination codon and the others interfere with
splicing of the gene [16–19]. No mutations within this gene
could be found in patients with van Buchem disease, but
instead a 52-kb deletion 35 kb downstream of the SOST
gene was identiﬁed [20, 21]. The deleted region was later
found to contain regulatory elements for SOST transcrip-
tion, explaining its ability to induce a phenotype closely
resembling that of patients with sclerosteosis [22]. The
different defects of the SOST gene cannot readily explain
the differences in clinical phenotypes between the two
diseases. It may be that the genomic region deleted in van
Buchem disease does not contain regulatory elements
required for sclerostin expression during digit formation,
which can be the reason for the absence of syndactyly (or
other digit malformations) in these patients as opposed to
patients with sclerosteosis.
SOST/Sclerostin Expression
SOST mRNA is, especially during embryogenesis,
expressed in many tissues, whereas sclerostin protein
expression has been reported only postnatally in terminally
differentiated cells embedded within a mineralized matrix,
i.e., osteocytes, mineralized hypertrophic chondrocytes,
and cementocytes [11, 12, 23, 24]. SOST mRNA expres-
sion in unmineralized tissues has been detected during
mouse embryogenesis in the otic vesicle and peridigital or
interdigital regions of the limb buds, of which the latter
may be implicated in the pathogenesis of syndactyly in
patients with sclerosteosis [25]. In humans, SOST mRNA is
expressed in the heart, aorta, and liver, with high levels in
the kidney [16, 17, 26, 27]; but no sclerostin protein has
Fig. 1 Chronological portraits
of a patient with sclerosteosis
from the age of 3 years onward.
She was born with syndactyly at
both hands and developed facial
palsy, deafness, facial
distortion, and maxillary
overgrowth during childhood.
By the age of 30, she had
developed proptosis and
elevated intracranial pressure
due to overgrowth of the
calvaria. Craniectomy was
performed, but she died
nevertheless because of elevated
intracranial pressure at the age
of 54 years (description of this
case was previously published
by Epstein et al. [13])
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123been detected in these organs. Accordingly, patients with
sclerosteosis or van Buchem disease do not have renal or
cardiovascular abnormalities [3].
In adult murine and human bone, sclerostin expression is
restricted to osteocytes, with diffuse staining representing
dendrites in osteocytic canaliculi [11, 23, 24, 28]. Osteo-
clasts, osteoblasts, and bone lining cells do not express
sclerostin. Due to the current inability to isolate osteocytes
from mammalian bone, in vitro studies of SOST/sclerostin
expression are technically difﬁcult. Osteogenic cell cul-
tures that form mineralized bone nodules are one of the few
available methods for generating osteocyte-like cells in
vitro [29]. In mouse primary osteogenic bone marrow and
mouse mesenchymal KS483 cell cultures, SOST mRNA
expression is induced at low levels after onset of bone
nodule mineralization [11, 30]. Similar to the induction of
SOST mRNA in vitro, newly embedded osteocytes within
unmineralized osteoid in humans in vivo do not express
sclerostin but become positive for the protein at, or shortly
after, primary mineralization [24]. When mineralization of
osteoid is inhibited by administration of the bisphospho-
nate etidronate in rats, osteocytes within the unmineralized
matrix remain immature and do not express sclerostin [31].
However, SOST mRNA is expressed by some osteoblast-
like osteosarcoma cell lines [32].
As expected, sclerostin is not expressed by osteocytes in
bone biopsies of patients with sclerosteosis [11]. In addi-
tion, no sclerostin expression was found in bone biopsies
from patients with van Buchem disease, supporting the
function of the genomic region deleted in these patients in
the regulation of sclerostin expression in bone [12].
Sclerostin Mechanism of Action
In patients with sclerosteosis, the combination of high bone
mass due to increased bone formation with premature ter-
mination codons in the SOST gene suggested an inhibitory
effect of the gene product sclerostin on bone formation.
This is supported by the observation that addition of
exogenous sclerostin to osteogenic cultures inhibited pro-
liferation and differentiation of mouse and human osteo-
blastic cells [11, 23, 33]. In addition, sclerostin was shown
to decrease the life span of osteoblasts by stimulating their
apoptosis [33]. In vivo, overexpression of sclerostin using
either the osteocalcin promoter or BAC recombination
induced osteopenia in mice [22, 23]. Bone formation in
these animals was decreased, while bone resorption was
unaffected. Furthermore, analysis of SOST knockout mice
showed signiﬁcant increases in radiodensity, bone mineral
density (BMD), cortical and trabecular bone volume, bone
formation rate, and bone strength [34]. Together these data
support a negative effect of sclerostin on bone formation.
Two processes are responsible for the construction and
reconstruction of the skeleton throughout life, bone
remodeling and modeling. Bone remodeling enables con-
stant renewal of the skeleton. In this process, bone
resorption by osteoclasts and formation by osteoblasts are
tightly coupled within a basic multicellular unit (BMU) and
bone resorption always precedes bone formation. Sclero-
stin expression by newly embedded osteocytes at the onset
of mineralization of osteoid may serve as a negative
feedback signal on osteoblasts to prevent overﬁlling of the
BMU (Fig. 2a) [11, 24]. Data on the effect of sclerostin on
osteoclastic bone resorption in humans are scarce and
inconsistent, with unaffected, low, or increased bone
resorption reported in patients with sclerosteosis and van
Buchem disease [9, 10, 15]. In addition, during bone
modeling sclerostin may keep bone lining cells in a qui-
escent state [24] and may thereby prevent activation of
osteoblasts and bone formation without previous bone
resorption (Fig. 2b) [8]. Sclerostin expression by osteo-
cytes embedded in newly formed bone by modeling may
serve a similar negative feedback mechanism on bone
formation as in a BMU.
On the basis of its amino acid sequence, which indicates
a cystine knot structure, sclerostin was classiﬁed as a
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Fig. 2 Schematic model of the mechanism of action of sclerostin in
bone remodeling and modeling. In remodeling a, sclerostin produced
and secreted by newly embedded osteocytes may be transported to the
bone surface, where it inhibits osteoblastic bone formation and
prevents overﬁlling of the BMU. In modeling b, sclerostin may serve
two actions. First, it may keep bone lining cells in a state of
quiescence and prevent, thereby, initiation of de novo bone formation.
In addition, sclerostin produced and secreted by newly embedded
osteocytes may inhibit osteoblastic bone formation, as in a BMU
(reproduced from van Bezooijen et al. [8])
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123member of the DAN (differential screening–selected gene
aberrant in neuroblastoma) family of glycoproteins [16, 17,
35, 36]. This family consists of a group of secreted proteins
that share the ability to antagonize bone morphogenetic
protein (BMP) activity. The available data, however, sug-
gest that sclerostin is not a classical BMP antagonist [11].
Some DAN family members have also been reported to
antagonize canonical Wnt signaling, among which Wise is
the most closely related to sclerostin [37]. Wnts are
secreted glycoproteins that bind to seven transmembrane-
spanning receptors of the Frizzled family. Stimulation of
these receptors causes the intracellular signaling molecule
b-catenin to accumulate and translocate into the nucleus,
where it initiates transcription of target genes via complex
formation with TCF/Lef1 transcription factors. Conversely,
in the absence of Wnt, b-catenin forms a complex with the
tumor-suppressor proteins APC and Axin and the kinases
glycogen synthase kinase 3 (GSK3) and casein kinase I
(CK1), which facilitates phosphorylation and proteosomal
degradation of b-catenin [38].
The identiﬁcation of gain-of-function mutations in the
ﬁrst b-propeller of the low-density lipoprotein receptor-
related protein LRP5, an essential membrane-bound
cofactor in canonical Wnt signaling, in patients with high
bone mass (HBM) phenotype [39, 40] and loss-of-function
mutations in LRP5 in patients with the osteoporosis pseu-
doglioma syndrome [41] demonstrated the importance of
LRP5-mediated canonical Wnt signaling in regulating bone
formation. Sclerostin has been shown to bind LRP5 and its
closely related coreceptor LRP6 and, thereby, inhibit the
canonical Wnt signaling (Fig. 3)[ 42–44]. However,
although sclerostin binds LRP5/6 to antagonize Wnt sig-
naling, sclerostin and Wnts do not appear to compete for
binding of this coreceptor [42]. It may be that sclerostin
exerts its effect through binding to a coreceptor and
inducing internalization of LRP5/6 as has been shown for
Dkk1, another Wnt antagonist. Characterization of the
structure of sclerostin showed that it indeed consists of a
cystine knot and three loops [45, 46]. One of these loops is
high in positively charged residues, showing a possible site
of interaction with the predicted binding site on the ﬁrst
b-propeller of LRP5, which is negatively charged. In
addition, the binding site of a neutralizing antibody to
sclerostin was mapped to this loop, suggesting a functional
role of this region in the inhibition of Wnt signaling. A
potential binding site for heparin was also found within
sclerostin, which may mediate localization of sclerostin at
the cell surface of target cells and possibly facilitate inhi-
bition of Wnt signaling.
The precise mechanism by which sclerostin secreted by
osteocytes inhibits Wnt-mediated bone formation is still
unclear. It may be transported to the bone surface via the
canaliculi, or it may induce another signal in osteocytes
that is transported to osteoblasts to inhibit bone formation.
In support of the latter, Wnt signaling has been found in
osteocytes [47, 48].
Recently, the role of bone-expressed LRP5 in the
regulation of bone formation was questioned since tar-
geted deletion of LRP5 in osteoblasts using the collagen
type 1 promoter failed to induce osteopenia and targeted
knock-in of LRP5 with an HBM mutation (G171V) using
the same promoter did not increase bone mass in mice
[49]. It was shown that LRP5-mediated signaling in the
duodenum inhibited the expression of Tph1, the rate-
limiting enzyme for serotonin production outside the
brain, and thereby decreased serum levels of serotonin.
Conversely, LRP5 knockout mice that have low bone
mass had high serum serotonin levels. In addition,
reduction of these elevated serotonin levels by adminis-
tration of parachlorophenylalanine or a low-tryptophan
diet normalized bone-formation parameters and bone
mass. These ﬁndings suggest a new mechanism for the
effect of LRP5-mediated signaling on bone mass, the
importance of which in human physiology is currently
unknown.
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Fig. 3 Schematic model of antagonized canonical Wnt signaling.
Canonical Wnt signaling involves the formation of complexes of
Wnts with Frizzled receptors and LRP5/6 coreceptors, resulting in the
accumulation of b-catenin in the cytoplasm and translocation into the
nucleus. The antagonist Dkk1 inhibits canonical Wnt signaling by
the formation of complexes with LRP5/6 and Kremen, resulting in the
removal of LRP5/6 from the membrane. Dkk1 binds to the ﬁrst and
third b-propellers of LRP5/6. The antagonist sclerostin inhibits
canonical Wnt signaling by binding to probably the ﬁrst b-propeller
of LRP5/6. Whether sclerostin requires a cofactor like Kremen for
Dkk1 to exert its antagonistic effect remains to be established
(reproduced from van Bezooijen et al. [8])
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Due to their location and morphology, osteocytes have
been long implicated in mechanosensing and initiation of
the bone anabolic response to mechanical load [50, 51]. In
support of this, speciﬁc ablation of osteocytes in mice
resulted in fragile bone, and these mice did not respond
with bone loss to unloading [52]. Wnt signaling may play
an important role in the anabolic response to deformation
and loading since increased Wnt signaling has been found
after loading of osteoblastic cells in vitro and of tibiae in
vivo [47, 53, 54] and the Wnt coreceptor LRP5 was found
to be essential for the increase in bone mass after loading
[55]. Since sclerostin is produced by osteocytes in bone and
inhibits bone formation by antagonizing canonical Wnt
signaling, it may play a role in regulating Wnt signaling in
response to mechanical loading. Consistent with this
hypothesis, loading decreased SOST mRNA and sclerostin
levels, while unloading increased SOST mRNA expression
in vivo (Fig. 4)[ 54, 56, 57]. Interestingly, reduction of
sclerostin staining intensity was most pronounced in areas
with the highest strain, indicating a response to local
loading conditions. Furthermore, SOST knockout mice do
not exhibit bone loss after unloading nor is canonical Wnt
signaling altered [54].
Several systemic and local factors have been suggested
as possible regulators of SOST/sclerostin expression by
osteocytes. Recombinant human PTH and active fragments
of this protein are used in the treatment of osteoporosis
[58]. In contrast to the bone resorption–stimulating effect
of continuous elevation of endogenous PTH, as is seen in
patients with hyperparathyroidism, intermittent increases
of PTH provided by daily injections are associated with
distinct anabolic effects. The mechanisms by which PTH
mediates this bone anabolic effect are not completely
understood. Part of it may be mediated via sclerostin as
PTH has been shown to inhibit its expression both in vitro
and in vivo (Fig. 4). In vitro, PTH decreased SOST tran-
scription by osteoblastic and osteocytic cells within 4 h.
This was not affected by the protein synthesis inhibitor
cyclohexamide but was decreased by the cAMP inducer
forskolin [28, 32]. These observations suggest a direct and
cAMP-dependent regulatory effect of PTH on the expres-
sion of SOST. Within the 52-kb genomic region deleted in
van Buchem disease, an MEF2 response element has been
identiﬁed that is essential for the PTH-induced downreg-
ulation of SOST expression [59]. In vivo, PTH adminis-
tration resulted in a decrease in SOST mRNA and sclerostin
expression in mice and rats [28, 32, 59, 60]. In addition, a
constitutively active PTH receptor 1 (caPTHR1) exclu-
sively expressed in osteocytes resulted in increased
remodeling with decreased osteoblast apoptosis and sup-
pression of SOST expression [61]. This effect was blunted
in mice lacking LRP5, suggesting that the effect of
caPTHR1 was mediated by increased Wnt signaling due to
suppression of SOST. The importance of SOST regulation
by PTH is further supported by the observations that the
anabolic effect of PTH is blunted in SOST-deﬁcient mice as
well as in mice overexpressing SOST using a constitutive
active promoter [62].
Two other systemic factors have also been shown to
affect SOST/sclerostin expression. 1,25-Dihydroxyvitamin
D3 alone or in combination with retinoic acid increased
SOST expression in human osteoblastic cells in vitro [30,
63]. The speciﬁc effect of glucocorticoids on SOST
expression depends on the experimental conditions. In
vitro, dexamethasone suppressed SOST expression in
osteoblastic cells [30], while in vivo treatment of mice with
prednisolone increased SOST expression in tibiae, sug-
gesting that suppression of Wnt signaling by the upregu-
lation of sclerostin may account for the glucocorticoid-
induced suppression in bone formation (Fig. 4)[ 64].
BMP2, -4, and -6 are local growth factors shown to
stimulate SOST expression in osteoblastic cells in vitro [25,
30]; and putative BMP responsive elements are present
within the SOST promoter region [65]. Decreased BMP
signaling due to osteoblast-speciﬁc knockout of BMPR1A
decreased SOST mRNA and sclerostin protein expression
in embryonic mice calvariae and was associated with
increased bone mass [65]. In these mice, however, both
bone formation and resorption were inhibited. The authors
proposed that the decrease in bone formation was inde-
pendent of sclerostin expression and a direct result of
decreased BMP signaling. The decrease in bone resorption,
-
Glucocorticoids
Intermittent PTH
Loading
sclerostin
↑Bone formation ↓Bone formation
+
Lining cells
Active osteoblasts
Osteocytes
Bone surface
Fig. 4 Schematic model for the regulation of the control of bone
formation by sclerostin. Sclerostin may exert its inhibitory effect on
bone formation by preventing the activation of lining cells as well as
the inactivation of active osteoblasts. Glucocorticoids stimulate
sclerostin expression and, thereby, inhibit bone formation, whereas
intermittent PTH and loading inhibit sclerostin expression in osteo-
cytes and, thereby, stimulate bone formation
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123however, may be an effect of increased Wnt signaling due
to the decrease in sclerostin expression. This in turn may be
due to upregulation of osteoprotegerin in mature osteo-
blasts by Wnts and, thereby, inhibition of RANKL-induced
osteoclastogenesis [66].
Despite the rapid progress in our understanding of the
regulation of the production and function of sclerostin,
there are still important questions that need to be addressed
in future research. These include the identiﬁcation of fac-
tors that regulate sclerostin/SOST expression and determine
its highly restricted expression pattern. Furthermore, the
mechanism by which sclerostin binding to LRP5/6 inter-
feres with canonical Wnt signaling as well as potential
additional functions of sclerostin, besides antagonizing
canonical Wnt signaling, need to be elucidated. More
detailed and structured analysis of bone metabolism in
patients with sclerosteosis and van Buchem disease, scle-
rostin expression in pathological conditions, and a geno-
type–phenotype characterization of SOST are required to
better understand its function and regulation in humans.
Therapeutic Potential
The identiﬁcation of sclerostin deﬁciency as the cause of
sclerosteosis and van Buchem disease and the progress in
our understanding of the action of sclerostin on bone for-
mation have opened a new area in bone therapeutics. The
restricted expression pattern of sclerostin and the exclusive
bone phenotype of good quality of patients with scleros-
teosis and van Buchem disease provide the basis for the
design of therapeutics that speciﬁcally stimulate bone for-
mation, an action relevant to the treatment of osteoporosis.
As sclerostin is a secreted protein, one approach to achieve
this is to develop antibodies capable of inhibiting the bio-
logical activity of sclerostin, mimicking, thus, its absence
in sclerosteosis. Such antibodies have already been shown
to increase BMD, bone volume, and bone strength in
ovariectomized rats [67] and primates [68] and to reverse
bone loss in a model of colitis [69]. Preliminary data from a
blinded, placebo-controlled, dose-escalating single-dose
study of 48 healthy postmenopausal women demonstrated
that a single injection of a monoclonal antibody against
sclerostin markedly increased bone-formation markers and
BMD and was well tolerated [70]. Serum P1NP levels
reached a peak 14–25 days after the antibody administra-
tion and progressively returned to baseline values after
about 2 months. In contrast, the bone-resorption marker
serum CTx decreased to a minimum about 14 days after
the antibody injection and returned to baseline values after
about 2 months. Clinical phase II studies are currently
under way. Other approaches to inhibit sclerostin produc-
tion or activity are also feasible. However, given the
availability of efﬁcacious treatments, any novel treatment
for osteoporosis should not only be effective but also
devoid of adverse effects. The absence of any extraskeletal
complications of patients with sclerosteosis and van Bu-
chem disease is reassuring. Furthermore, the ﬁnding of
consistently higher BMD values in carriers of sclerosteosis
with no skeletal complications [6] suggests that sclerostin
inhibition can be titrated and can lead to the desired out-
come without any side effects, but safety margins need to
be determined. However, there have been concerns that
stimulation of bone formation by increasing Wnt signaling
may lead to unwanted skeletal effects [71, 72]. The Wnt
inhibitor factor 1 (WIF1), for example, has been identiﬁed
as a candidate tumor-suppressor gene in human osteosar-
coma, suggesting that the susceptibility to osteosarcoma
may be increased in patients receiving novel anabolic
treatments targeting Wnt antagonists [73]. This is another
issue that needs to be further investigated.
Study of the molecular defects of rare bone disorders
such as sclerosteosis and van Buchem disease can, thus,
lead to the development of new bone-forming agents,
allowing us to tailor pharmacotherapy to the needs of the
individual patient with osteoporosis. In addition, it may
help in the management of the small group of patients with
sclerosteosis or van Buchem disease, for whom the only
available treatment is the technically difﬁcult and often
risky removal of excess bone tissue from the skull.
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